Compound and pharmaceutical composition containing the same
Through novel compounds, the generation of neurites and cell regeneration is promoted, and the problem of difficult treatment of nerve damage and diseases in the prior art is solved, and the fundamental treatment and prevention of nerve cells is achieved, and the side effects of drug toxicity are reduced.
Patent Information
- Application Number
- CN202080101209.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-06-12
- Filing Date
- 2020-08-25
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-08-25
AI Technical Summary
The prior art is difficult to effectively treat or prevent nerve damage, neurological diseases and developmental disorders caused by nerve cell death. Current treatment methods are limited to relieving symptoms and lack methods that can promote nerve cell regeneration.
Provides a novel compound that induces or promotes the generation, growth, differentiation, regeneration and proliferation of neurites through specific chemical structures, combines retinoic acid derivatives to form pharmaceutical compositions for the treatment or prevention of nerve damage, diseases and developmental disorders .
This compound can directly promote the regeneration and differentiation of nerve cells, reduce cytotoxicity, improve solubility and solubility stability, reduce the side effects of drug toxicity, and significantly improve the protection effect of nerve regeneration and differentiation.
Smart Images

Figure CN115836057B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to novel compounds and pharmaceutical compositions containing the same for treating or preventing neural damage, neural diseases or developmental disorders by promoting the proliferation, differentiation and / or regeneration of neural cells. Background Art
[0002] Nerve cells are distributed in many parts of the body, including the brain. The body can sense external conditions, think, react, and move through signal transmission between nerve cells. Therefore, when nerve cells die for some reason, various symptoms such as cognitive impairment, paralysis, sensory impairment, and movement abnormalities may appear. Alzheimer's disease is caused by the death of nerve cells in the part responsible for memory in the brain, and Parkinson's disease is caused by the death of nerve cells in the part that regulates body movement.
[0003] Once nerve cells die, it is difficult to regenerate. Other cells such as skin cells undergo cell division to produce new cells that can replace them even if they are damaged due to injury. However, nerve cells are different from other cells and do not undergo cell division. Therefore, it is very difficult to treat diseases related to the death of nerve cells. For this reason, so far, the treatment of many diseases caused by the death of nerve cells has only been studied to alleviate the symptoms. Therefore, it is still required to develop substances that can effectively treat or prevent nerve damage, nerve diseases, and developmental disorders through the regeneration of nerve cells. Summary of the invention
[0004] One object of the present invention is to provide novel compounds and pharmaceutical compositions containing the novel compounds that can effectively treat or prevent nerve damage, nerve diseases or developmental disorders.
[0005] The aforementioned object of the present invention can be achieved by providing a compound represented by the following Chemical Formula 1 and a pharmaceutical composition containing the compound.
[0006]
Chemical formula 1
[0007]
[0008] In the chemical formula 1,
[0009] R 1 To R 3 Each independently represents hydrogen, a linear or branched (C1-C10) alkyl group, or an electron pair for forming any bond,
[0010] A represents *-(CH2) n -A 1 -*,
[0011] n represents any integer from 0 to 5,
[0012] A 1 Indicates *-COO-*, *-CO-*, *-NR 4 -*, *-CH2-*, *-CONH-* or *-O-*,
[0013] Linking group indicates *-L 1 -NHCO-L 2 -*, *-L 1 -OROL 2 -*, *-L 1 -CH2-L 2 -*, *-L 1 -NR 5 -L 2 -* or *-L 1 -COO-L 2 -*,
[0014] L 1 represents a straight chain or branched (C1-C30) alkyl group,
[0015] L 2 represents a single bond, or a straight chain or branched (C1-C30) alkyl group,
[0016] R represents a straight chain or branched (C1-C20) alkyl group,
[0017] R 4 and R 5 Each independently represents hydrogen, or a linear or branched (C1-C10) alkyl group,
[0018] B represents a moiety derived from retinoic acid.
[0019] Effects of the Invention
[0020] So far, the treatment of nerve damage or nerve degeneration and various diseases related thereto is at the level of alleviating the development of the disease, and the therapeutic agent for the complete treatment of the disease does not yet exist. The compound according to the present invention can directly induce or promote the generation of neurite, the growth of neurite, the differentiation of nerve cells, the regeneration of nerve cells and / or the proliferation of nerve cells, and therefore can provide a fundamental treatment to various nervous system diseases. Meanwhile, the cytotoxicity is low, so the side effect caused by drug toxicity is few. In addition, the solubility and dissolution stability to water are high, so that the dosage form flexibility of the preparation is high, and the absorption rate in the body increases, so nerve regeneration, differentiation, protective effect can be more improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The photographs show the state of the compound of the present invention (MMB-11903B) and ATRA (comparative compound, all-transretinoic acid) immediately after being dissolved in water and the dissolved state of the compounds after being left to stand for 20 minutes.
[0022] Figure 2a is a graph showing the neuronal cell survival rate according to the concentration of ATRA and the elapsed time. Figure 2b It is a graph which shows the neuronal cell survival rate according to the concentration of the MMB-11903B compound and the elapsed time.
[0023] Figure 3a is a graph showing neuronal cytotoxicity according to the concentration of ATRA and the elapsed time. Figure 3b It is a graph showing the neuronal cytotoxicity according to the concentration of the MMB-11903B compound and the elapsed time.
[0024] Figure 4 The photographs show the morphology of neural cells according to the concentration and treatment time of DO3A or MMB-11903B compound.
[0025] Figure 5a The photos were taken by staining the neural cell lines treated with DO3A or MMB-11903B compounds with markers for neural cell differentiation and then photographing them using a fluorescence microscope. Figure 5b This is a graph showing the measured changes in the length of neurites of nerve cells after treatment with DO3A or MMB-11903B compound.
[0026] Figure 6a The photos were obtained by staining the neural cell lines treated with ATRA or MMB-11903B compound with markers for neural cell differentiation and then photographing them using a fluorescence microscope. Figure 6b This is a graph showing the expression level measured by color histogram using an antibody against a marker for neural cell differentiation in order to confirm the differentiation of neural cells treated with ATRA or the compound MMB-11903B of the present invention.
[0027] Figure 7a The photographs are obtained by staining the neural cell lines treated with DO3A, ATRA or the compound MMB-11903B of the present invention with a marker for neural cell proliferation and then photographing them with a fluorescence microscope. Figure 7bThis is a graph showing the ratio of the number of positive cells using the Ki-67 antibody in order to confirm the proliferation of neural cells treated with DO3A, ATRA or the compound of the present invention, MMB-11903B. DETAILED DESCRIPTION
[0028] The following terms used in this application are used only to illustrate specific embodiments and are not intended to limit the present invention. Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meanings as generally understood by people with ordinary knowledge in the technical field to which the present invention belongs. The same terms defined in commonly used dictionaries should be interpreted as having meanings consistent with the meanings in the context of the relevant technology, and should not be interpreted as ideal or overly formal meanings when not clearly defined in this application.
[0029] According to one aspect of the present invention, a compound represented by the following Chemical Formula 1 is provided.
[0030]
Chemical formula 1
[0031]
[0032] In the chemical formula 1, R 1 To R 3 Each independently represents hydrogen, a linear or branched (C1-C10) alkyl group, or an electron pair for forming any bond. Specifically, in the chemical formula 1, R 1 To R 3 Each may independently represent hydrogen, a linear or branched (C1-C3) alkyl group, or an electron pair for forming any bond. More specifically, it may represent hydrogen or an electron pair for forming any bond. Further specifically, it may be hydrogen.
[0033] In addition, in the chemical formula 1, A represents *-(CH2) n -A 1 -*.
[0034] In addition, in the chemical formula 1, n represents any integer from 0 to 5. Specifically, in the chemical formula 1, n may represent any integer from 1 to 5, and more specifically, may represent any integer from 1 to 3.
[0035] In addition, in the chemical formula 1, A 1 Indicates *-COO-*, *-CO-*, *-NR 4 -*, *-CH2-*, *-CONH-* or *-O-*. Specifically, A 1 Can represent *-COO-*, *-CO-*, *-NR 4-* or *-CONH-*, more specifically, can represent *-CONH-*.
[0036] In addition, in the chemical formula 1, the linking group represents *-L 1 -NHCO-L 2 -*, *-L 1 -OROL 2 -*, *-L 1 -CH2-L 2 -*, *-L 1 -NR 5 -L 2 -*or*-L 1 -COO-L 2 -*. Specifically, the linking group may represent *-L 1 -NHCO-L 2 -*or*-L 1 -NR 5 -L 2 -*, more specifically, can mean *-L 1 -NH-L 2 -*.
[0037] In addition, in the chemical formula 1, L 1 represents a straight chain or branched (C1-C30) alkyl group. 1 It may represent a linear or branched (C1-C10) alkyl group, and more specifically, may represent a linear or branched (C1-C5) alkyl group.
[0038] In addition, in the chemical formula 1, L 2 represents a single bond, or a linear or branched (C1-C30) alkyl group. 2 It may represent a single bond, or a linear or branched (C1-C10) alkyl group, more specifically, it may represent a single bond, or a linear or branched (C1-C5) alkyl group, and further specifically, it may represent a single bond.
[0039] In addition, in the chemical formula 1, R represents a linear or branched (C1-C20) alkyl group. Specifically, R may represent a linear or branched (C1-C10) alkyl group, and more specifically, may represent a linear or branched (C1-C5) alkyl group.
[0040] In addition, in the chemical formula 1, R 4 and R 5 Each independently represents hydrogen, or a linear or branched (C1-C10) alkyl group. 4 and R 5 can be independently hydrogen, or a linear or branched (C1-C5) alkyl group. More specifically, R4 It can be hydrogen. In addition, more specifically, R 5 It may be hydrogen.
[0041] In addition, in the chemical formula 1, B represents a part derived from retinoic acid. The retinoic acid may include isomers of retinoic acid such as all-trans retinoic acid (hereinafter referred to as ATRA), 13-cis retinoic acid, 9-cis retinoic acid, etc. Specifically, B may represent the following chemical formula 2a, 2b or 2c:
[0042]
Chemical formula 2a
[0043]
[0044]
Chemical formula 2b
[0045]
[0046]
Chemical formula 2c
[0047]
[0048] The chemical formula 2a is a moiety derived from ATRA, the chemical formula 2b is a moiety derived from 13-cis retinoic acid, and the chemical formula 2c is a moiety derived from 9-cis retinoic acid.
[0049] According to an implementation example of the present invention, in the chemical formula 1, B may represent the chemical formula 2a.
[0050] According to another embodiment of the present invention, the compound of the present invention can be in the chemical formula 1, n represents any integer from 1 to 5, A 1 Represents *-CONH-*.
[0051] According to another embodiment of the present invention, the compound of the present invention can be in the chemical formula 1, the linking group represents *-L 1 -NR 5 -L 2 -*, R 5 For hydrogen.
[0052] According to another embodiment of the present invention, the compound of the present invention can be in the chemical formula 1, L 1 represents a straight chain or branched (C1-C10) alkyl group, L 2 Represents a single bond.
[0053] According to another embodiment of the present invention, the compound of the present invention can be in the chemical formula 1, wherein R 1 To R 3Each independently represents hydrogen, a straight or branched (C1-C3) alkyl group or an electron pair for forming any bond, and A represents *-(CH2) n -A 1 -*, n represents any integer from 1 to 5, A 1 Indicates *-COO-*, *-CO-*, *-NR 4 -* or *-CONH-*, the linking group represents *-L 1 -NHCO-L 2 -* or *-L 1 -NR 5 -L 2 -*,L 1 represents a straight chain or branched (C1-C10) alkyl group, L 2 represents a single bond, or a linear or branched (C1-C10) alkyl group, R represents a linear or branched (C1-C10) alkyl group, R 4 and R 5 Each independently represents hydrogen, or a linear or branched (C1-C5) alkyl group, and B is represented by the chemical formula 2a, 2b or 2c.
[0054] According to another embodiment of the present invention, the compound of the present invention can be in the chemical formula 1, wherein R 1 To R 3 Each independently represents hydrogen or an electron pair used to form any bond, and A represents *-(CH2) n -A 1 -*, n represents any integer from 1 to 3, A 1 represents *-CONH-*, and the linking group represents *-L 1 -NR 5 -L 2 -*,L 1 represents a straight chain or branched (C1-C10) alkyl group, L 2 represents a single bond, R represents a straight chain or branched (C1-C10) alkyl group, R 5 is hydrogen, and B is represented by the chemical formula 2a, 2b or 2c.
[0055] The compound of Chemical Formula 1 according to the present invention can be prepared, for example, by reacting the compound of the following Chemical Formula 1-1 with a retinoic acid derivative. The retinoic acid derivative can be L defined in Chemical Formula 1. 2 The precursors, such as succinimide, are bound to retinoic acid in the form of.
[0056]
Chemical formula 1-1
[0057]
[0058] In the chemical formula 1-1, A and L 1 Same as defined in Chemical Formula 1.
[0059] According to one aspect of the present invention, a pharmaceutical composition containing the compound of the aforementioned Chemical Formula 1 or a pharmaceutically acceptable salt thereof is provided.
[0060] The compound of Chemical Formula 1 according to the present invention is useful for inducing or promoting the generation of neurites, the growth of neurites, the differentiation of nerve cells, the regeneration of nerve cells and / or the proliferation of nerve cells in response to nerve damage, nerve diseases or developmental disorders.
[0061] The term "neurite" refers to a projection extending from the cell body of a nerve cell, including, for example, an axon and a dendrite.
[0062] To this end, according to one aspect of the present invention, there is provided a pharmaceutical composition containing the compound of the present invention or a pharmaceutically acceptable salt thereof for inducing or promoting the generation of neurites, the growth of neurites, the differentiation of neurons, the regeneration of neurons and / or the proliferation of neurons.
[0063] In addition, according to another form of the present invention, a method for inducing or promoting the generation of neurites, the growth of neurites, the differentiation of neurons, the regeneration of neurons or the proliferation of neurons is provided, the method comprising the step of administering a compound of the present invention or a pharmaceutically acceptable salt thereof to an object or a neuron requiring the generation of neurites, the growth of neurites, the differentiation of neurons, the regeneration of neurons or the proliferation of neurons.
[0064] According to one aspect of the present invention, there is provided a pharmaceutical composition for treating or preventing nerve damage, nerve disease or developmental disorder, characterized in that it contains the compound of the present invention or a pharmaceutically acceptable salt thereof.
[0065] The term "treatment" used in this specification achieves a preferred therapeutic effect on the object, including reducing the rate of development, stopping the rate of development, alleviating symptoms, improving the morbid state and curing the morbid state. The compound according to the present invention can provide a fundamental cure for the disease through the morphological and functional repair of damaged cells, and for this reason, the treatment specifically refers to the treatment of the disease through the morphological and functional repair of nerve cells. In addition, the term "prevention" can refer to the use of an object that is not currently ill, but is at risk of morbidity.
[0066] The term "nerve injury" refers to any injury to the nervous system such as spinal cord injury or optic nerve injury, including, for example, injury to the nervous system induced by trauma or chemical induction (e.g., induced by neurotoxins or treatment methods with immunosuppressive effects) or induced by disease or disorder. In addition, the nerve injury includes injury to the central nervous system (CNS) and injury to the peripheral nervous system (PNS), more specifically cranial nerve injury, spinal cord injury, optic nerve injury, peripheral nerve injury, etc.
[0067] The term "neurological disease" includes degenerative neurological diseases, ischemic neurological diseases and peripheral nerve diseases. The "degenerative neurological diseases" specifically include degenerative brain diseases (e.g., memory loss, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, etc.), amyotrophic lateral sclerosis, ataxia, convulsions, etc. The "ischemic neurological disease" specifically includes ischemic brain diseases (e.g., ischemic stroke). The "peripheral nerve disease" specifically includes polyneuropathy, mononeuropathy, mononeuritis multiplex and autonomic neuropathy.
[0068] The term "developmental disorder" includes disorders of brain and neurodevelopmental development.
[0069] As also understood in the embodiments described later, the compound of the present invention can generate and grow the neurites of nerve cells, differentiate, regenerate and proliferate nerve cells, and therefore, the mixture of the present invention or the pharmaceutical composition containing its pharmaceutically acceptable salt can be used as the purpose of treating or preventing nerve damage, neurological diseases or developmental disorders. At the same time, the compound of the present invention can also be very useful as a learning ability enhancer or cognitive function improver.
[0070] In addition, according to another aspect of the present invention, a method for treating or preventing neural damage, neural disease or developmental disorder is provided, which method comprises the step of administering a compound of the present invention or a pharmaceutically acceptable salt thereof to a subject in need of treatment or prevention of neural damage, neural disease or developmental disorder.
[0071] According to an embodiment of the present invention, there is provided a pharmaceutical composition for treating or preventing brain nerve damage, degenerative brain disease or ischemic brain disease, characterized in that it contains the compound of the present invention or a pharmaceutically acceptable salt thereof.
[0072] According to another embodiment of the present invention, there is provided a pharmaceutical composition for treating or preventing dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, convulsions, memory loss or ischemic stroke, characterized in that it contains a compound of the present invention or a pharmaceutically acceptable salt thereof.
[0073] According to another embodiment of the present invention, there is provided a pharmaceutical composition for treating or preventing peripheral nerve injury, spinal cord injury, optic nerve injury, amyotrophic lateral sclerosis, ataxia or peripheral nerve disease, characterized in that it contains a compound of the present invention or a pharmaceutically acceptable salt thereof.
[0074] According to another embodiment of the present invention, there is provided a pharmaceutical composition for treating or preventing brain neurodevelopmental disorders, characterized in that it contains the compound of the present invention or a pharmaceutically acceptable salt thereof.
[0075] In the pharmaceutical composition of the present invention, the compound of Chemical Formula 1 according to the present invention can be used in the form of a pharmaceutically acceptable salt. The "pharmaceutically acceptable salt" is a compound salt that maintains the pharmacological activity of the parent compound, for example, (i) a salt formed by an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid; (ii) a salt formed by an organic acid such as acetic acid, propionic acid, isobutyric acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; (iii) a salt formed when the acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth metal ion or an aluminum ion; (iv) a ligand with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine; or (v) a salt of an amino acid such as alginic acid.
[0076] In addition, the pharmaceutical composition of the present invention may contain an isomer, solvate or prodrug of the compound of the chemical formula 1 of the present invention. Wherein, "isomer" includes all possible stereoisomers including diastereomers and enantiomers. The compound of the present invention should be understood to refer to a mixture of all possible stereoisomer forms. In addition, the term "solvate" refers to a complex of a solute (e.g., a compound of chemical formula 1) and a solvent, and when the solvent is water, the solvate may refer to a hydrate. The term "prodrug" refers to a compound that is converted into an active compound with pharmacological effect by absorption and metabolism in the organism after administration to the organism. The prodrug itself is an inactive compound or a compound that is less active than the active compound, however, it can provide properties that are beneficial to processing, administration or metabolism. The prodrug may be an ester form of an active compound (e.g., a physiologically acceptable metabolically unstable ester) or a form of a saccharide derivative or an amino acid ester derivative.
[0077] The pharmaceutical composition of the present invention may contain the compound represented by the chemical formula 1 or a pharmaceutically acceptable salt thereof alone, but may also contain a pharmaceutically acceptable carrier on this basis. The pharmaceutically acceptable carrier may be a conventionally used one in the field of pharmacy, such as an excipient (e.g., starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, etc.) or a diluent (e.g., physiological saline, purified water, etc.).
[0078] In addition, as needed, the pharmaceutical composition of the present invention may contain, in addition to the pharmaceutically acceptable carrier, pharmaceutically acceptable additives such as binders, disintegrants, lubricants, coating agents, film coating bases, enteric film coating bases, flexible capsule bases, dissolution aids, emulsifiers, suspending agents, stabilizers, buffers, antioxidants, surfactants, sweeteners, bittering agents, preservatives, thickeners, aromatics or colorants.
[0079] The pharmaceutical composition of the present invention can be administered orally or parenterally. When administered parenterally, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. When administered orally, the pharmaceutical composition of the present invention can be formulated into a solid or liquid dosage form. Solid dosage forms can be, for example, tablets, capsules (flexible & hard capsules), powders, granules, pills, lozenges, etc., and liquid dosage forms can be, for example, elixirs, suspensions, emulsions, solutions, syrups, lemonades, etc. When it is a tablet, in addition to the active ingredient, a carrier such as lactose, corn starch, etc.; a lubricant such as magnesium stearate, etc.; a binder such as methylcellulose, microcrystalline cellulose, polyvinyl alcohol, etc.; a disintegrant such as bentonite, sodium alginate, etc., etc. can also be added. In the case of a liquid preparation, the active ingredient can be formulated together with a carrier such as purified water, physiological saline, etc., and, if necessary, a dissolution aid such as sucrose monostearate, a stabilizer such as polyvinyl pyrrolidone, etc.; in the case of an oral aqueous suspension preparation, the active ingredient can be formulated together with a suspension preparation, and, if necessary, a surfactant, a preservative, a stabilizer, etc.
[0080] The dosage of the pharmaceutical composition of the present invention can be determined in consideration of the administration method, the age, sex, severity, condition, inactivation rate of the patient, and concomitant drugs, and can be administered once or multiple times.
[0081] Hereinafter, for a detailed understanding of the present invention, representative compounds of the present invention are given to illustrate the properties of the compounds according to the present invention, the preparation methods thereof, and the pharmaceutical compositions containing the compounds. However, the present invention is not limited to the following examples.
[0082] 1. Preparation Examples of Compounds According to the Present Invention
[0083]
[0084] 1) Synthesis of compound a
[0085]
[0086] All trans retinoic acid (4 g, 13.31 mmol) was dissolved in 90 ml of THF, and then DCC (4.12 g, 19.97 mmol) was added and stirred for 30 minutes. N-hydroxysuccinimide (NHS; 2.30 g, 19.97 mmol) solution dissolved in 30 ml of THF was added dropwise at 4°C, and the mixture was reacted at room temperature for 18 hours. After filtering the generated solid, the solvent was removed, and the mixture was dissolved in dichloromethane (DCM) again, and purified by passing through a silica gel column to obtain compound a. Yield: 4.6 g (87.0%)
[0087] 2) Synthesis of Compound A
[0088]
[0089] DO3A( t BuO)3 (10 g, 19.43 mmol) was dissolved in 320 ml of acetonitrile (ACN), and KHCO3 (5.93 g, 59.26 mmol) was added, and stirred at room temperature for 30 minutes. Ethyl bromoacetate (2.36 ml, 21.37 mmol) was added dropwise to the mixture, and after stirring at 70°C for 24 hours, the inorganic salt was filtered to remove the solvent of the reactant. The reaction was vacuum dried to obtain compound A as a yellow solid. Yield: 11.5 g (99%)
[0090] 3) Synthesis of Compound B
[0091]
[0092] After adding ethylenediamine (60 ml, 846.1 mmol) to compound A (25.4 g, 42.30 mmol), stir at room temperature for 4 days. After the reaction is completed, add 150 ml of brine solution, and extract repeatedly 3 times with 150 ml of DCM solution to obtain an organic solvent layer. After dehydration with Na2SO4, remove the solvent, and perform column chromatography under DCM / MeOH electrolyte conditions for purification. After adding hexane to the obtained compound, stir at room temperature to obtain compound B as a white solid. Yield: 10.43 g (40.2%)
[0093] 4) Synthesis of Compound C
[0094]
[0095] Compound B (3 g, 4.88 mmol) was dissolved in DCM (12 ml / 48 ml, v / v) containing 20% trifluoroacetic acid (TFA), and then heated under reflux at 40°C for 24 hours. While adding MeOH, the solvent was repeatedly evaporated under reduced pressure for about 3 times, then dissolved in MeOH again and precipitated in ether. The obtained white solid was dissolved in distilled water and precipitated again in acetone to obtain a purified white solid compound C. Yield: 1.37 g (62.9%)
[0096] 5) Synthesis of compound MMB-11903B
[0097]
[0098] Compound C (0.2 g, 0.36 mmol) was dissolved in MeOH, and N,N-diisopropylethylamine (DIPEA) (0.62 ml, 3.57 mmol) was added, and then stirred at room temperature for 3 hours. Compound a (0.17 g, 0.43 mmol) was added, and after heating and reflux at 60°C for 24 hours, it was precipitated in ether to obtain a light yellow solid. Isopropyl alcohol (IPA) was added to the compound, and after heating, it was cooled and the generated compound was filtered to obtain compound MMB-11903B. Yield: 0.09 g (34.3%)
[0099] 2. Solubility test
[0100] In order to confirm the solubility of the compound according to the present invention, the compound MMB-11903B and ATRA prepared in the preparation example were added to 1 mL of deionized water at a concentration of 100 mM (the compound MMB-11903B of the present invention: 72.8 mg / mL, ATRA: 30.0 mg / mL), and gently vortexed to dissolve. The state just after dissolution was photographed. Figure 1 After the prepared solution of the compound MMB-11903B of the present invention and the ATRA solution were allowed to stand at room temperature for 20 minutes, photos were taken again to observe the dissolution state of the compound in each solution ( Figure 1 ).
[0101] like Figure 1As shown, the compound MMB-11903B and ATRA of the present invention are uniformly dissolved in the solution at the initial stage, but ATRA separates from the solution and precipitates as time passes. On the contrary, the compound MMB-11903B of the present invention does not separate from the solvent and can maintain a uniform dissolved state even if it is left to stand for the same time as ATRA. It can be confirmed that the compound MMB-11903B of the present invention can be easily dissolved in a solvent such as water, and thus has not only high solubility but also dissolution stability, so that even if it is left to stand for a long time, it can maintain a dissolved state. The solubility and dissolution stability of the compound MMB-11903B of the present invention are very excellent compared to ATRA.
[0102] 3. Cytotoxicity Assay
[0103] 3-1) Cell viability test
[0104] The human neuroblastoma SH-SY5Y, an undifferentiated neural cell line, was used as the object, and the cell viability (cell activity) of the neural cell line was analyzed using CCK-8. For reference, the CCK-8 (Cell counting kit-8) was analyzed using the highly water-soluble tetrazolium salt-SST-8, and the analysis was based on the following points: [2-(methoxy-4-nitrophenyl)-3-(4-nitrophenyl)(2,4-disulfonylbenzene)-2H-tetrazolyl monosodium salt] generates a water-soluble formazan orange dye when it is reduced in the presence of an electrolyte. The amount of formazan dye generated by dehydrogenase in the cell is directly proportional to the number of surviving cells. The specific experimental method is as follows.
[0105] SH-SY5Y cells were grown in Minimum Essential Medium (MEM) supplemented with 10% Fetal bovine serum (FBS), 1% Antibiotic-Antimycotic (AA), and 2 mM L-Glutamine. To analyze cell survival, the stabilized cells were cultured at 1×10 4The cells were floated in 200 μL of culture medium at a density of 100 μL / well and planted in each well of a 96-well plate. They were attached in a constant temperature incubator at 37°C and 5% CO2 for more than 14 hours and waited for stabilization. The next day, the growth medium was removed, and in order to induce differentiation, the compound MMB-11903B of the present invention synthesized in the preparation example and the all-trans retinoic acid (hereinafter referred to as ATRA) as a comparative compound were diluted at various concentrations (0, 1, 2, 5, 10, 20, 30, 50 μM) in 100 μL Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12 (DMEM / F-12=1:1) culture medium supplemented with 1% FBS, 1% AA, and 2mM L-glutamine, and cultured at 37°C and 5% CO2 for 24, 48, and 72 hours. 2 hours before harvesting, 10 μL of CCK-8 solution was added to each well, and cultured for a further 2 hours. For the wells that completed the culture, the absorbance was measured at 450 nm using a microplate reader.
[0106]
Cell survival rate calculation formula
[0107]
[0108] (In the formula, A is the absorbance value measured in the control well, and B is the absorbance value measured in the well to which the drug was added.)
[0109] For the calculated values, the graphs were drawn using the GraphPad Prism application. The statistical significance of the calculated values was confirmed by one-way ANOVA with Dunnett's multiple comparison test. *p<0.5, ***p<0.01 vs. 24h control, #p<0.5, ###p<0.01 vs. 48h control, The difference was significant compared with 72h control. Figure 2a and Figure 2b The results for ATRA and the compound of the present invention, MMB-11903B, are shown separately.
[0110] exist Figure 2a and 2bIn the experiment, when the 24-hour survival rate, 48-hour survival rate, and 72-hour survival rate when the concentration of ATRA or compound MMB-11903B was 0 μM (i.e., when ATRA and compound MMB-11903B were not administered at all) were set to 100%, the higher the concentration of ATRA and the longer the time, the lower the cell survival rate (reference Figure 2a ). On the contrary, it can be confirmed that the 72-hour survival rate of the case where the compound MMB-11903B of the present invention is administered is always higher than that of the case where the compound MMB-11903B of the present invention is not administered, so it can be confirmed that the compound MMB-11903B of the present invention can improve the cell survival rate as the administration time passes. In particular, at a concentration of 50 μM, the 72-hour survival rate of the compound MMB-11903B of the present invention is about 2 times higher than that of ATRA. It is thus confirmed that the toxicity of MMB-11903B to nerve cells is also reduced under long-term exposure.
[0111] 3-2) Cells analyzed by lactate dehydrogenase (LDH) Toxicity test
[0112] Cytotoxicity (cell death) can be indirectly measured by cell viability test, but in order to measure more sensitively and accurately, it is verified by using enzymes related to cell death or cell damage. Lactate dehydrogenase (LDH) is a stable enzyme present in the cytoplasm, which is usually not discharged outside the cell without passing through the cell membrane, but is released into the culture medium when the cell membrane is damaged or the cell dies. Therefore, the amount of LDH in the culture medium is proportional to the number of dead or damaged cells, and the amount of LDH is thus measured.
[0113] SH-SY5Y was grown in Minimum Essential Medium (MEM) supplemented with 10% Fetal bovine serum (FBS), 1% Antibiotic-Antimycotic (AA), and 2 mM L-Glutamine. To analyze cell survival, the stabilized cells were cultured at 2.5 × 10 4The cells were floated in 200 μL of culture medium at a density of 100 μL / well and planted in each well of a 96-well plate. They were attached in a constant temperature incubator at 37°C and 5% CO2 for more than 14 hours and waited for stabilization. The next day, the growth medium was removed, and in order to induce differentiation, the compound MMB-11903B prepared in the preparation example of the present invention and all-trans retinoic acid (ATRA) were diluted at various concentrations (0, 1, 5, 10, 20, 30, 50, 100, 200 μM) in 100 μL Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12 (DMEM / F-12=1:1) culture medium supplemented with 1% FBS, 1% AA, and 2mM L-glutamine, and cultured at 37°C and 5% CO2 for 24, 48, and 72 hours. To a new 96-well plate, 100 μL of LDH reaction mixture (D-Plus) was added to the upper layer of 10 μL of the culture medium of the ramet. TM LDH kit, Cat. No. LDH-500) was used to react in the dark for 30 minutes. For the well plate after incubation, the absorbance was measured at 450 nm using an ELISA reader.
[0114]
Cytotoxicity calculation formula
[0115] Cytotoxicity (%) = (AB) / (CB) × 100 (%)
[0116] (In the above formula, A is the absorbance value of the group to which the drug was added, B is the absorbance value of the group not treated with the drug, and C is the absorbance value of the maximum amount of LDH that can be released in the cells after adding 10 μL of lysis solution to the cells used in the experiment.)
[0117] For the calculated values, the graphs were drawn using the GraphPad Prism application. The statistical significance of the calculated values was confirmed by one-way ANOVA with Dunnett's multiple comparison test. ***p<0.01 vs. 24h control, ###p<0.01 vs. 48h control, The difference was significant compared with 72h control. Figure 3a and Figure 3b The results for ATRA and the compound of the present invention, MMB-11903B, are shown separately.
[0118] exist Figure 3a In the experiment, ATRA began to show cytotoxicity at a concentration of about 30 μM, and when cultured at a concentration of 200 μM for 24 hours, the cytotoxicity was about 55%. Figure 3b In the experiment, the compound MMB-11903B of the present invention began to show cytotoxicity at a concentration of about 100 μM, and when cultured at a concentration of 200 μM for 24 hours, the cytotoxicity was about 5%. It can be confirmed that the compound MMB-11903B of the present invention is significantly less cytotoxic than ATRA (for example, when cultured at a concentration of 200 μM for 24 hours, the cytotoxicity of the compound MMB-11903B of the present invention is more than 10 times lower than that of ATRA).
[0119] 4. Confirm the effect on nerve cells
[0120] 4-1) Changes in the morphology of nerve cells
[0121] SH-SY5Y was grown in Minimum Essential Medium (MEM) supplemented with 10% Fetal bovine serum (FBS), 1% Antibiotic-Antimycotic (AA), and 2 mM L-Glutamine. To analyze cell survival, the stabilized cells were cultured at 4 × 10 5 The cells were planted in a 60 nm dish at a density of 100 cells / dish. The cells were attached in a constant temperature incubator at 37°C and 5% CO2 for more than 14 hours and allowed to stabilize. The next day, the growth medium was removed, and in order to induce differentiation, the compound MMB-11903B prepared in the preparation example of the present invention and DO3A of the following chemical formula were diluted at various concentrations (0, 5, 10, 20 μM) in Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12 (DMEM / F-12=1:1) medium supplemented with 1% FBS, 1% AA, and 2 mM L-glutamine, and cultured at 37°C and 5% CO2 for 1, 3, and 5 days. For the morphology of the cells, images were obtained using a Nikon inverted microscope (Nikon, ECLIPSE Ts2, Nikon Corporation, Tokyo, Japan). Figure 4 The images of the neural cell lines treated with DO3A or the compound of the present invention, MMB-11903B, are shown in FIG.
[0122] [Chemical formula of DO3A]
[0123]
[0124] When the compound MMB-11903B of the present invention is treated, changes in cell morphology can be observed from a low concentration. Differentiation into neurons is induced, so that the cell body becomes smaller, and the neurites, which are precursors of axons and dendrites, proliferate (neurite outgrowth), so that their length becomes more than twice that of the cell body. Over time, the proliferation of neurites further expands, and the formation of neurite networks becomes obvious. Compared with the compound MMB-11903B of the present invention, when DO3A is treated, no proliferation of neurites is observed, but cell death due to cytotoxicity is observed from 10 μM, 5 days and 20 μM, 3 days. It is confirmed that DO3A does not have a neuronal differentiation function, but causes toxicity and participates in neuronal cell death. In contrast, in the compound MMB-11903B of the present invention having a backbone of DO3A, cytotoxicity is improved, and not only that, differentiation into neurons is induced.
[0125] 4-2) Immunofluorescence staining of neurites Proliferation promotion Effect test
[0126] SH-SY5Y was grown in Minimum Essential Medium (MEM) supplemented with 10% Fetal bovine serum (FBS), 1% Antibiotic-Antimycotic (AA), and 2 mM L-Glutamine. To analyze cell survival, the stabilized cells were cultured at 4 × 10 5The cells were planted in a 60 nm dish at a density of 100 / dish. They were attached in a constant temperature incubator at 37°C and 5% CO2 for more than 14 hours and allowed to stabilize. The next day, the growth medium was removed, and in order to induce differentiation, the compounds MMB-11903B and DO3A prepared in the preparation examples of the present invention were treated at a concentration of 10 μM in Dulbecco's Modified Eagle Medium / NutrientMixture F-12 (DMEM / F-12=1:1) medium supplemented with 1% FBS, 1% AA, and 2mM L-glutamine, and cultured at 37°C and 5% CO2. The cells harvested on the 1st, 3rd, and 5th days after culture were washed with DPBS, fixed in 10% neutral formalin for 10 minutes, washed 3 times in Tris-buffered saline, and reacted in 0.3% Triton X-100 (in TBS) for 15 minutes. After washing three times in TBS, a solution of 5% bovine serum albumin (BSA) and normal goat serum (Normal Goat Serum) (in TBS) was added and reacted at 4°C for 24 hours. A primary antibody against β-III tubulin was used as a neuron specific marker, and a primary antibody against doublecortin was used as a newborn immature neuron marker to confirm the differentiation of nerve cells and the induction of neurites. After reacting the primary antibody at 4°C for 24 hours, the cells were washed three times in TBS, and a secondary antibody was reacted at room temperature with Alexa Fluor. 488 dye (fluorescent) (green) and Alexa 555 dye (fluorescent) (red) for 1 hour. The cells were washed three times in TBS and mounted (Vector anti-fluorescence extraction and quenching mounting medium; VECTASHIELD Mounting Medium with DAPI; Vector Laboratories, Burlingame, CA, USA), and images were obtained using a fluorescence microscope. Figure 5a The image thus obtained is shown in FIG. Figure 5a As shown, when the compound of the present invention, MMB-11903B, was treated, neurite outgrowth and neurite network formation became apparent, whereas when DO3A was treated, no neurite outgrowth was observed.
[0127] The length of the proliferative processes was measured using ImageJ software. Only the length of the neurites that were more than twice the length of the cell body was measured. The calculated values were plotted using the GraphPad Prism application. Figure 5b The graph is shown in . The statistical significance of the calculated values was confirmed by one-way ANOVA with Dunnett's multiple comparison test. It is shown that *p<0.5, ***p<0.01 vs. control, ##p<0.1, ###p<0.01 vs. DO3A are significant. After fluorescent staining with a neural cell marker, the result of measuring the length of the neurite was that DO3A, which belongs to the backbone of MMB-11903B, was the same as the control group and did not show the proliferation of neurites. Compared with the control group and the DO3A-treated group, the neurite proliferation induction of the neural cells of the compound MMB-11903B of the present invention increased by an average of 1.7 times on the first day, an average of 2.6 times on the third day, and an average of 2.5 times on the fifth day.
[0128] 4-3) Neurite outgrowth by immunofluorescence staining and Tests on the generation and growth of new neurons
[0129] Furthermore, in the same manner as the above method, ATRA was used as a comparative compound instead of DO3A to observe neural cell differentiation by immunofluorescence staining. Figure 6a An image obtained using a fluorescence microscope is shown in FIG.
[0130] Color histograms were measured using ImageJ software, and the calculated values were graphed using GraphPad Prism application. Figure 6b The graph is shown in . Compared with the control group (untreated group) and the ATRA treated group as the positive control group, it was confirmed that by treating the compound MMB-11903B of the present invention, the differentiation and expression of nerve cells increased from the 3rd day, and it also maintained high expression until the 5th day. Compared with the low expression of newborn neurons maintained in the control group and the positive control group ATRA treated group, it was confirmed that the expression of newborn neurons began to increase significantly on the 3rd day. The statistical significance of the calculated values was confirmed by one-way ANOVA with Dunnett's multiple comparison test. It is shown that *p<0.5, ***p<0.01vs.control, #p<0.5, ##p<0.1, ###p<0.01vs.ATRA is significant.
[0131] 4-4) Test of cell proliferation effect using immunofluorescence staining Test
[0132] The number of positive cells was compared for Ki-67, a marker for neural cell proliferation, and the number of positive cells was automatically obtained using ImageJ software. Figure 7a A photograph obtained using a fluorescence microscope is shown in FIG.
[0133]
Calculation formula for the number of Ki-67 positive cells
[0134] Ki-67positive cells (%)=(ki-67positive cell number / DAPI positive cell number)X 100
[0135] For the calculated values, graphs were drawn using the GraphPad Prism application. Figure 7b The graph is shown in . On the first day of exposure, the DO3A and compound MMB-11903B treatment groups of the present invention showed nearly 2 times of cell proliferation compared to the control group (untreated group), and ATRA did not show significant differences from the control group. On the third day of exposure, except for the ATRA treatment group, neural cell proliferation was shown in all groups, and the compound MMB-11903B of the present invention showed a high neural cell proliferation rate until the fifth day. It was confirmed that the compound MMB-11903B of the present invention not only promoted differentiation into neural cells, but also induced the proliferation of new neural cells. The statistical significance of the calculated values was confirmed by one-way ANOVA with Dunnett's multiple comparison test. Shown for *p<0.5, **p<0.1, ***p<0.01vs.control, #p<0.5, ##p<0.1vs.DO3A, The difference was significant compared with ATRA.
[0136] It can be confirmed from the above Examples 4-1 to 4-4 that the compound MMB-11903B of the present invention can induce the proliferation of neurons in neural cell lines, compared with DO3A or ATRA as a control group, and maintain this proliferation. At the same time, it can be confirmed that it induces the formation and proliferation of neurites, thereby promoting differentiation into neurons.
[0137] The above description is made with reference to the preferred embodiments of the present invention. However, it should be understood that those skilled in the art may make various modifications and changes to the present invention without departing from the concept and scope of the present invention as described in the patent claims.
Claims
1. A compound represented by the following chemical formula 1: 【Chemical formula 1】 In the chemical formula 1, R 1 To R 3 Each independently represents hydrogen, A represents *-(CH 2 ) n -A 1 -*, n represents any integer from 0 to 5, A 1 represents *-CONH-*, Linker means *-L 1 -NR 5 -L 2 -*, L 1 represents a straight or branched C1-C30 alkyl group, L 2 represents a single bond, or a straight or branched C1-C30 alkyl group, R 5 represents hydrogen, or a linear or branched C1-C10 alkyl group, and said B represents the following chemical formula 2a, 2b or 2c: 【Chemical formula 2a】 【Chemical formula 2b】 【Chemical formula 2c】 2. The compound according to claim 1, It is characterized in that The B represents Chemical Formula 2a.
3. The compound according to claim 1, It is characterized in that The n represents any integer from 1 to 5.
4. The compound according to claim 1, It is characterized in that R 5 For hydrogen.
5. The compound according to claim 1, It is characterized in that The L 1 represents a straight or branched C1-C10 alkyl group, wherein L 2 Represents a single bond.
6. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition according to claim 6, It is characterized in that Used to treat or prevent nerve damage, neurological disease, or developmental disorders.
8. The pharmaceutical composition according to claim 7, It is characterized in that The pharmaceutical composition is used for treating or preventing brain nerve damage, degenerative brain disease or ischemic brain disease.
9. The pharmaceutical composition according to claim 7, It is characterized in that The pharmaceutical composition is used for treating or preventing dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, convulsions, memory loss or ischemic stroke.
10. The pharmaceutical composition according to claim 7, It is characterized in that The pharmaceutical composition is used for treating or preventing peripheral nerve injury, spinal cord injury, optic nerve injury, amyotrophic lateral sclerosis, ataxia or peripheral nerve disease.
11. The pharmaceutical composition according to claim 7, It is characterized in that The pharmaceutical composition is used for treating or preventing brain nerve developmental disorders.
